Summary:
Click image to enlargeSuven Life Sciences (Suven) has begun a study of an investigational drug (also known as the “study drug”) called SUVN-G3031 as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy, which means you have a sleep disorder that causes daytime drowsiness with or without muscle weakness.
Qualified Participants May Receive:
Suven appreciates your involvement in this study. The following payments will be made to compensate you for your time and to reimburse you for transportation or parking payments related to visiting the study center:
You will receive $74 for visit 1 and 5. You will receive $250 for each overnight stay. You will be reimbursed after the final completed visit.